StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →6-factor scoring with sector-relative rank. Updated daily.
Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
Next report date, year-over-year trend, and recent quarter history.
5-factor analysis: Valuation, Growth, Profitability, Momentum, Financial Health.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-11 | $4.85 | $4.80 | -1.03% | 0.3M |
| 05-12 | $4.80 | $4.64 | -3.33% | 0.3M |
| 05-13 | $4.57 | $4.66 | +1.92% | 0.4M |
| 05-14 | $4.62 | $4.47 | -3.25% | 0.3M |
| 05-15 | $4.33 | $4.48 | +3.46% | 0.5M |
Earnings (▲ beat / ▼ miss) and ex-dividend dates plotted on the price line. Educational — proximity does not establish causation.
Each factor shows PRLD's percentile within the scored universe — observational ranking, not a recommendation.
Aggregated from Polygon's per-article sentiment classifications. Educational — sentiment is descriptive, not predictive.
Past 1 reported quarters: EPS surprise vs estimate and the day-after-release stock reaction. Past performance does not predict future moves.
Sources: Finnhub earnings calendar + Polygon daily aggregates. Reaction direction can diverge from EPS surprise (guidance, macro, or sector flow can dominate the next-day print).
| Metric | Q3 2026 (Est.) Expected 2026-08-12 | Q1 2026 2026-03-31 | Annual 2025 2025-12-31 | Q3 2025 2025-09-30 | Q1 2025 2025-03-31 |
|---|---|---|---|---|---|
Revenue | $0.00 | $4.58M | $12.14M | $6.50M | $0.00 |
Operating Income | Not available | $-14.18M | $-104.57M | $-87.22M | $-34.61M |
Net Income | Not available | $-10.38M | $-99.50M | $-83.04M | $-32.09M |
EPS (Diluted) | $-0.23 | $-0.13 | $-1.29 | $-1.09 | $-0.42 |
Total Assets | Not available | $119.64M | $141.31M | $94.75M | $141.26M |
Total Liabilities | Not available | $59.46M | $72.68M | $36.22M | $38.08M |
Cash & Equivalents | Not available | $21.76M | $35.26M | $47.53M | $40.27M |
Free Cash Flow OCF − CapEx | Not available | $-21.68M | $-56.37M | $-79.49M | $-34.28M |
Shares Outstanding | Not available | 82.52M | 76.96M | 76.04M | 75.99M |
No sell-side coverage available for PRLD.
Common for small-cap names, ETFs, recent IPOs, and ADRs without US-listed sell-side coverage. When analysts publish, ratings appear here within one business day.
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
Prelude Therapeutics Incorp is a precision oncology company developing medicines in areas of high unmet need for cancer patients. Its pipeline features selective KAT6A degraders and mutant selective JAK2V617F JH2 inhibitors, new approaches to clinically validated targets with transformative potential for patients. The company is also leveraging its expertise in targeted protein degradation to discover and develop next-generation degrader antibody conjugates (DACs) with novel payloads.